Financing channel feed – Endpoints News

Financing channel feed

On heels of positive COPD readout, Verona to provide new public offering

3 years ago

Karuna looks to build on positive schizophrenia data with one of the biggest public raises this year

3 years ago

With SPACs' high tide long gone, Blue Water ditches second blank check voyage

3 years ago

Sofinnova, Forbion back $70M push across finish line for rare antifungal treatment

3 years ago

Days after an FDA approval for its psoriasis drug, Arcutis looks to raise $150M in public capital

3 years ago

Gene therapy biotech uses its manufacturing sites as collateral to net a $100M loan

3 years ago

BeiGene co-founder and ex-Viela Bio BD leader snag $200M for age-related biotech, with ARCH jumping in

3 years ago

French biotech armed with Series A looks to build out manufacturing facility for plant-based protein tech

3 years ago

New biotech from Alexis Borisy will test Merck KGaA, Blueprint cancer drug combo in bid to fulfill Gleevec promise

3 years ago

Exclusive: UPMC launches another biotech, rooted in the tumor microenvironment

3 years ago

A new AI startup, launched with a trio of Fred Hutch vets, wants to give a 'zoomed-in' view of cancer cells

3 years ago

Lexicon hops on public offering train to prepare for next year's potential drug approval

3 years ago

'Tip of the iceberg': Novartis-partnered UC Berkeley lab churns out a startup to tackle protein stabilization

3 years ago

Gilead again backs AlloVir's T cell therapy in $127M direct offering

3 years ago

A year after netting Takeda partnership, small molecule startup arms itself with some new cash

3 years ago

RA Capital jumps on board diabetes biotech, pitching in on $160M Series D

3 years ago

Legend seeks $250M after positive #ASCO22 data, but challenges remain for the J&J partner

3 years ago

Another SPAC goes by the wayside as Innovatus ditches its blank check vehicle

3 years ago

NewAmsterdam's bid to revive Amgen cardio drug heads to Nasdaq in Frazier SPAC deal

3 years ago

With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies

3 years ago

Updated: Gritstone goes the credit facility route, securing $80M to keep clinical efforts running

3 years ago

One year after leaving GSK, Emmanuel Hanon jumps to Medicxi-backed vaccine startup with an eye on RSV

3 years ago

Armed with a $48M Series A, Auron is looking to apply machine learning in cancer treatment

3 years ago

'Not in today's market': As Amgen, Bristol Myers back antibody startup BigHat, bear market keeps IPO window shut tight

3 years ago

First page Previous page 49 50 515253 54 55 Next page Last page